| Bcl2 and ROS1 expression in human meningiomas: an analysis with respect to histological subtype. | meningiomas, |
| ROS1 gene was first identified as an oncogene in NSCLC through a phosphoproteomic screen, leveraging the fact that oncogenic kinases should be highly phosphorylated proteins. | lung, |
| New targetable oncogenes in non-small-cell lung cancer. | lung, |
| Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(m etheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. | lymphoma,brain, |
| The aim of this study was to demonstrate the role of fused-in-glioblastoma-c-ros-oncogene1 (FIG-ROS) fusion gene in Intrahepatic cholangiocarcinoma.[FIG-ROS] | liver,cholangiocarcinoma,glioblastoma, |
| Development of lung adenocarcinomas with exclusive dependence on oncogene fusions. | lung, |
| Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. | lung, |
| report adds the ZCCHC8-ROS1 fusion as oncogenic driver in GBM and supports the role of ROS1 activation in the pathogenesis of a subset of glioblastoma | GBM,glioblastoma, |
| ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations. | lung, |
| ROS1 rearrangements rarely overlap with alterations in EGFR, KRAS, ALK, or other targetable oncogenes in NSCLC. | lung, |
| Studies suggest that the routine clinical use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) may be replaced by emerging next-generation sequencing and digital, color-coded barcode technologies, which have the advantage of simultaneously evaluating anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) and epidermal growth factor receptor (EGFR) alterations in a single analysis. | lymphoma, |
| GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors. | pediatric,glioma, |
| Expression of the ROS1 oncogene for tyrosine receptor kinase in adult human meningiomas. | meningiomas, |
| Expression and localization of c-ros oncogene along the human excurrent duct. | None |
| Localization of the 5 end of the MCF2 oncogene to human chromosome 15q15----q23. | None |
| Replacement of the human insulin receptor transmembrane and cytoplasmic domains by corresponding domains of the oncogene product v-ros leads to accelerated internalization, degradation, and down-regulation. | None |
| The ortholog of the human proto-oncogene ROS1 is required for epithelial development in C. elegans. | None |
| Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. | None |
| Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. | None |
| Specific inhibition of tyrosine kinase activity by an antibody to the v-ros oncogene product. | None |